PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17694307-11	2007	Blocking experiments and biodistribution studies confirmed the VEGFR specificity of (64)Cu-DOTA-VEGF(DEE).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	88-95	kinase insert domain receptor	Homo sapiens	63-68	
18784964-11	2009	CONCLUSION: The tumor uptake of (64)Cu-DOTA-VEGF(121) measured by small-animal PET imaging reflects tumor VEGFR-2 expression level in vivo.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	36-43	kinase insert domain receptor	Homo sapiens	106-113	
17694307-5	2007	The DOTA conjugates were tested in vitro for VEGFR-2 specificity and functional activity.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	4-8	kinase insert domain receptor	Homo sapiens	45-52	
17694307-9	2007	MicroPET imaging studies revealed that both (64)Cu-DOTA-VEGF(121) and (64)Cu-DOTA-VEGF(DEE) had rapid and prominent activity accumulation in VEGFR-2-expressing 4T1 tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	48-55	kinase insert domain receptor	Homo sapiens	141-148	
17694307-9	2007	MicroPET imaging studies revealed that both (64)Cu-DOTA-VEGF(121) and (64)Cu-DOTA-VEGF(DEE) had rapid and prominent activity accumulation in VEGFR-2-expressing 4T1 tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	74-81	kinase insert domain receptor	Homo sapiens	141-148	
17694307-12	2007	CONCLUSION: We have developed a VEGFR-2-specific PET tracer, (64)Cu-DOTA-VEGF(DEE).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	65-72	kinase insert domain receptor	Homo sapiens	32-39	
17138749-8	2006	Small-animal PET revealed rapid, specific, and prominent uptake of (64)Cu-DOTA-VEGF(121) in small U87MG tumors (high VEGFR2 expression) but significantly lower and sporadic uptake in large U87MG tumors (low VEGFR2 expression).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	71-78	kinase insert domain receptor	Homo sapiens	117-123	
17138749-8	2006	Small-animal PET revealed rapid, specific, and prominent uptake of (64)Cu-DOTA-VEGF(121) in small U87MG tumors (high VEGFR2 expression) but significantly lower and sporadic uptake in large U87MG tumors (low VEGFR2 expression).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	71-78	kinase insert domain receptor	Homo sapiens	207-213	
17138749-10	2006	Blocking experiments, immunofluorescence staining, and western blot confirmed the VEGFR specificity of (64)Cu-DOTA-VEGF(121).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	107-114	kinase insert domain receptor	Homo sapiens	82-87	
17138749-11	2006	CONCLUSION: Successful demonstration of the ability of (64)Cu-DOTA-VEGF(121) to visualize VEGFR expression in vivo may allow for clinical translation of this radiopharmaceutical for imaging tumor angiogenesis and guiding antiangiogenic treatment, especially patient selection and treatment monitoring of VEGFR-targeted cancer therapy.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	62-66	kinase insert domain receptor	Homo sapiens	90-95	
17138749-11	2006	CONCLUSION: Successful demonstration of the ability of (64)Cu-DOTA-VEGF(121) to visualize VEGFR expression in vivo may allow for clinical translation of this radiopharmaceutical for imaging tumor angiogenesis and guiding antiangiogenic treatment, especially patient selection and treatment monitoring of VEGFR-targeted cancer therapy.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	62-66	kinase insert domain receptor	Homo sapiens	304-309